Dark Forest Capital Management LP boosted its position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 568.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,369 shares of the biopharmaceutical company’s stock after buying an additional 2,865 shares during the quarter. Dark Forest Capital Management LP’s holdings in Xencor were worth $94,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in XNCR. Quadrant Capital Group LLC raised its holdings in Xencor by 19.5% during the 4th quarter. Quadrant Capital Group LLC now owns 2,606 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 426 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Xencor by 48.4% during the 1st quarter. Tower Research Capital LLC TRC now owns 2,438 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 795 shares during the period. Point72 Asset Management L.P. purchased a new position in Xencor during the 4th quarter valued at $73,000. Lazard Asset Management LLC increased its position in Xencor by 203.0% during the 1st quarter. Lazard Asset Management LLC now owns 4,485 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 3,005 shares during the period. Finally, Envestnet Asset Management Inc. increased its position in Xencor by 388.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 82,450 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 65,587 shares during the period.
Xencor Price Performance
Shares of XNCR stock opened at $21.25 on Friday. Xencor, Inc. has a one year low of $21.22 and a one year high of $38.20. The company’s 50-day moving average is $23.48 and its 200 day moving average is $26.53.
Wall Street Analyst Weigh In
XNCR has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Xencor in a research report on Monday, May 15th. Bank of America initiated coverage on shares of Xencor in a research report on Friday, May 19th. They set a “buy” rating and a $42.00 price objective on the stock. StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, August 25th. Piper Sandler upped their target price on shares of Xencor from $42.00 to $45.00 in a research report on Monday, August 7th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $37.00 target price on shares of Xencor in a research report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.20.
Read Our Latest Stock Report on Xencor
Insider Buying and Selling at Xencor
In other Xencor news, CEO Bassil I. Dahiyat sold 33,497 shares of the company’s stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of $26.19, for a total transaction of $877,286.43. Following the transaction, the chief executive officer now owns 292,216 shares in the company, valued at approximately $7,653,137.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.97% of the company’s stock.
Xencor Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Featured Articles
- Five stocks we like better than Xencor
- Best Aerospace Stocks Investing
- These 3 Wood Stocks are about to go on Discount
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Same Coin, Different Sides: 2 Observability Stocks Reverse Ways
- Best Stocks Under $5.00
- 3 Stocks Awaiting Winter Winds of Opportunity
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR – Free Report).
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.
